Apnimed (APMD) vs Collegium Pharmaceutical (COLL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Apnimed is the larger company by market cap ($751.0 million vs $713.9 million), about 1.1 times the size. On valuation, Apnimed trades at a lower trailing P/E (2.6x vs 17.3x for Collegium Pharmaceutical).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APMD | COLL |
|---|---|---|
| Share price | $18.04 | $21.93 |
| Market cap | $751.02M | $713.94M |
| 1-day change | -3.27% | +0.23% |
| YTD return | — | -52.63% |
| 1-year return | — | -34.32% |
| 5-year return | — | +4.53% |
| P/E ratio (TTM) | 2.59 | 17.27 |
| Forward P/E | — | 3.30 |
| EPS (TTM) | $6.96 | $1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $35.29 | $50.79 |
| 52-week low | $16.12 | $21.43 |
| Distance from 52-week high | -48.88% | -56.82% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +178.99% | +123.44% |
| Average volume | 558.59K | 747.73K |
| Shares outstanding | 41.63M | 32.56M |
| Employees | 81 | 423 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Collegium Pharmaceutical trades at a higher earnings multiple (17.3x vs 2.6x trailing P/E).
About Apnimed
APMD stock →Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets.
Healthcare · Biotechnology · 81 employees
About Collegium Pharmaceutical
COLL stock →Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Healthcare · Drug Manufacturers - Specialty & Generic · 423 employees
APMD vs COLL FAQ
Which is bigger, Apnimed or Collegium Pharmaceutical?
Apnimed (APMD) is larger, with a market capitalization of $751.02M compared with $713.94M for Collegium Pharmaceutical (COLL).
Which has the lower P/E ratio, APMD or COLL?
APMD has the lower trailing P/E at 2.6, versus 17.3 for COLL. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Apnimed and Collegium Pharmaceutical in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for Apnimed and Drug Manufacturers - Specialty & Generic for Collegium Pharmaceutical.